Luteolysis is a key event in Ovsynch programs of lactating dairy cows. Studies indicate that as many as 20% of cows treated with a Presynch/Ovsynch program have delayed or incomplete luteolysis using dinoprost tromethamine. Cows must have complete luteolysis to have a chance to become pregnant. Dinoprost tromethamine has a short half-life of approximately 7 to 8min. Cloprostenol sodium is more resistant to endogenous metabolism and is maintained in circulation for a longer time (half-life=3h). The objective was to determine if cloprostenol sodium could increase the percentage of cows with complete luteolysis and subsequent pregnancy per artificial insemination (P/AI) in lactating dairy cows compared with dinoprost tromethamine when administered within a presynchronization plus Ovsynch program for first artificial insemination (n=652) and an Ovsynch resynchronization program for second or later AI (second+; n=394). Blood samples were collected daily for 5 d beginning at the PGF(2α) of Ovsynch in a subset of cows (n=680) for first and second+ AI to measure circulating concentrations of progesterone (P(4)) and estradiol (E(2)). Complete luteolysis was defined as cows with functional corpus luteum (CL) at time of treatment and serum concentrations of P(4) <0.5 ng/mL at 56, 72, and 96 h after treatment. Percentage of cows with functional CL that had complete luteolysis after treatment was not greater for cloprostenol sodium compared with dinoprost tromethamine in first (79 vs. 80%, respectively) or second+ AI (70 vs. 72%, respectively). In addition, mean serum concentrations of P(4) were not less for cows treated with cloprostenol sodium following treatment. Pregnancy per AI of cows treated with cloprostenol sodium tended to be greater than dinoprost tromethamine for first (40 vs. 35%; respectively) but not second+ AI (23 vs. 21%, respectively). Cows with greater serum P(4) concentrations at time of PGF(2α) of Ovsynch had a greater probability of undergoing complete luteolysis after PGF(2α) of Ovsynch and pregnancy at 39 d after timed AI (i.e., 50% pregnant at 8 vs. 28% pregnant at 4 ng/mL P(4)). Serum concentrations of E(2) at 56 h after PGF(2α) of Ovsynch were a positive predictor of pregnancy at 39 d after timed AI. In summary, cloprostenol sodium tended to improve P/AI. Cows with greater serum concentrations of P(4) at time of PGF(2α) of Ovsynch had a greater chance of luteolysis and pregnancy.
Dairy cow infertility negatively affects profit of dairy production enterprises around the world, and enhancing conception rates of dairy cows is a critical management issue to resolve. It appears that conception rates of dairy cows are attenuated due to reduced progesterone concentrations in circulation during growth of the ovulatory follicle. It is not clear how reduced progesterone influences fertility, but data presented in this brief review suggest that it can be somewhat reversed through increasing concentrations of progesterone during the growth of the ovulatory follicle before luteolysis. Ovsynch protocols may be utilised to enhance progesterone concentrations through the induction of an accessory corpus luteum (CL) following the initial gonadotropin-releasing hormone (GnRH) treatment. Cows at Day 13 of the oestrous cycle with a 7-day-old accessory CL had ~50% more progesterone at the time of prostaglandin injection of Ovsynch compared with cows with only a Day 13 CL. Ovsynch can consistently induce an accessory CL following the initial GnRH treatment if cows are on Days 6 or 7 of the oestrous cycle at the time of treatment. Pre-synchrony strategies are critical to enhance the probability that cows will be on Days 6 or 7 at first GnRH treatement of Ovsynch.
The objective of this experiment was to determine the effect of high versus low progesterone (P4) during the pre-dominance or dominance phase (or both) of ovulatory follicle development on follicular dynamics and fertility of lactating dairy cows. Progesterone (P4) was manipulated to reach high (H) or low (L) serum concentrations during the pre-dominance phase (d 0 to 4 of the wave) and dominance phase (d 5 to 7 of the wave) of a second follicular wave ovulatory follicle, creating 4 treatments: H/H, H/L, L/H, and L/L. Luteolysis was induced with PGF on d 7 of the wave and ovulation was induced with GnRH 56 h after PGF. Cows (n = 558) received artificial insemination (AI) 16 h following GnRH. Pregnancy was determined at 6 intervals during gestation and at calving to quantify pregnancy loss beginning at d 23 post-AI utilizing pregnancy-specific protein B (PSPB) in novel within-cow comparisons. Cows with single ovulations assigned to the L/L treatment had greater pre-ovulatory follicle diameter compared with cows assigned to the L/H or H/L treatments. Cows with single ovulations had greater pre-ovulatory follicle diameter compared with cows with double ovulations. Low P4 in H/L, L/H, and L/L increased double ovulation rate compared with H/H. Cows with double ovulations had greater pregnancies per AI (P/AI) on d 23 post-AI compared with cows with single ovulations but had greater losses if ovulations were unilateral. Cows with low P4 during the entire period of the ovulatory follicle development also had greater P/AI on d 23 post-AI compared with cows with high P4 during both phases. However, full-term P/AI was not different between treatments. This was a result of the greater incidence of pregnancy losses between d 35 and 56 of gestation for cows with unilateral double ovulations compared with bilateral double ovulations and single ovulatory cows. Cows with single ovulation and low circulating P4 during the dominance period of follicle development had increased pregnancy losses between d 35 and 56 of gestation compared with cows with single ovulations and high P4. The PSPB measurements on d 16 and 23 post-AI were highly accurate in the prediction of pregnancy at d 28. The PSPB differed on d 23 and 28 between cows that had versus cows that did not have pregnancy losses between d 28 and 35 of gestation. In summary, circulating concentrations of P4 during ovulatory follicle development affected numbers of follicles ovulated and timing of subsequent pregnancy losses.
The objective was to determine the effect of sequence of insemination after simultaneous thawing of multiple 0.5 mL semen straws on conception rate in suckled multiparous Nelore cows. The effect of this thawing procedure on in vitro sperm characteristics was also evaluated. All cows (N = 944) received the same timed AI protocol. Ten straws (0.5 mL) of frozen semen from the same batch were simultaneously thawed at 36 °C, for a minimum of 30 sec. One straw per cow was used for timed AI. Frozen semen from three Angus bulls was used. Timed AI records included sequence of insemination (first to tenth) and time of semen removal from thawing bath. For laboratory analyses, the same semen batches used in the field experiment were evaluated. Ten frozen straws from the same batch were thawed simultaneously in a thawing unit identical to that used in the field experiment. The following sperm characteristics were analyzed: sperm motility parameters, sperm thermal resistance, plasma and acrosomal membrane integrity, lipid peroxidation, chromatin structure, and sperm morphometry. Based on logistic regression, there were no significant effects of breeding group, body condition score, AI technician, and sire on conception rate, but there was an interaction between sire and straw group (P = 0.002). Semen from only one bull had decreased (P < 0.05) field fertility for the group of straws associated with the longest interval from thawing to AI. However, the results of the laboratory experiment were unable to explain the findings of the field experiment. Sperm width:length ratio of morphometric analysis was the single sperm characteristic with a significant interaction between sire and straw group (P = 0.02). It was concluded that sequence of insemination after simultaneous thawing of 10 semen straws can differently affect conception rates at timed AI, depending on the sire used. Nevertheless, the effects of this thawing environment on in vitro sperm characteristics, remain to be further investigated.
Objetivo: O presente estudo tem como propósitos identificar os fatores que influenciam a adesão da gestante ao acompanhamento pré-natal e destacar os principais cuidados com a gestante soropositiva durante o pré-natal, parto e puerpério.Materiais e Métodos: Trata-se de uma revisão integrativa da literatura, com análise baseada em níveis de evidências. Os dados foram obtidos através da busca em bases de dados virtuais em saúde.Resultados: Treze estudos compuseram a amostra, sendo que o maior índice foi de evidências moderadas, seis (46,1%) estudos. Os principais cuidados à gestante soropositiva durante o pré-natal, parto e puerpério foram: uso da terapia antirretroviral, evidenciado em sete (53,8%) estudos, seguido do teste Anti-HIV e da preocupação em orientar as puérperas a não amamentar destacados em seis (46,1%) estudos.Conclusão: Torna-se necessária a implantação de uma assistência de qualidade às gestantes soropositivas, evidenciando a necessidade de estratégias de educação permanente para sensibilizar, mobilizar e capacitar profissionais envolvidos no cuidado, visando, assim, à prevenção da transmissão vertical do HIV para o recém-nascido e à melhora na qualidade de vida da gestante.
The probability of a pregnancy decreases substantially in lactating dairy cows treated with Ovsynch if luteolysis is delayed or incomplete. Two PGF(2α) products are currently approved in the United States for luteolysis in lactating dairy cattle, dinoprost tromethamine and cloprostenol sodium. Cloprostenol has a longer half-life compared with dinoprost, is more resistant to endogenous metabolism, and is maintained in circulation longer. We hypothesized that cloprostenol could reduce the time to complete luteolysis compared with dinoprost because of differences in half-life. Lactating dairy cows received the same presynchronization strategy (G6G; 25mg of PGF(2α) - 2 d - 100 μg of GnRH - 6 d - 100 μg of GnRH - 7 d - final PGF(2α) treatment). At the time of the final PGF(2α), cows (n=35) were randomly assigned to receive either 500μg of cloprostenol or 25mg of dinoprost. Blood samples were collected daily before and serially after PGF(2α) treatment to analyze circulating concentrations of progesterone (P(4)) and estradiol (E(2)). Ultrasound examinations of ovaries were performed to measure sizes of follicles and corpora lutea (CL) and determine time of ovulation. Considering only cows with complete luteolysis, mean circulating P(4) was lower for cows given cloprostenol than for those given dinoprost between 0 and 12h postinjection, but not at 24, 36, or 48 h. A rapid decrease in P(4) was observed 1h after PGF(2α) (6.54 ± 0.27 to 3.77 ± 0.22 ng/mL) followed by a complete rebound 1h later (3.77 ± 0.22 to 5.07 ± 0.31 ng/mL) followed by a steady decline in both treatment groups. Serum concentrations of E(2) were greater at 48 h posttreatment in cloprostenol-treated cows (2.74 ± 0.15 pg/mL) than in dinoprost-treated cows (2.37 ± 0.19 pg/mL). Cows that did not have complete luteolysis did not ovulate (0/7) during the 6-d period following treatment. Time to complete luteolysis and ovulation was 29.1 ± 1.1 versus 29.4 ± 1.7 and 101 versus 103 h posttreatment in cloprostenol compared with dinoprost. A negative relationship was observed between P(4) at 12h posttreatment and concentrations of E(2) 48 h posttreatment (b=-0.6905; R(2)=0.23). In summary, cows treated with cloprostenol had lower concentrations of P(4) for the first 12h following treatment and subsequently greater concentrations of E(2) compared with dinoprost, although no differences were observed in these 2 PGF(2α) analogs for time to complete luteolysis or time to ovulation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.